Efficacy and @entity137 of @entity1814 and XXXX with radiation treatment for advanced @entity418 .

@entity1 @entity137 @entity417 @entity882 @entity5 @entity957 @entity900 @entity1721 @entity1814 @entity418 @entity3 @entity1349 @entity1431 @entity1487
BACKGROUND: @entity1814 , a new analog of @entity900 , has been developed and marketed in recent years in Japan. In this study, we evaluated the efficacy and @entity137 of a regimen of @entity1814 and @entity1487 with radiation in @entity1 with advanced @entity418 . MATERIALS AND METHODS: Between June 1999 and December 2002, 42 @entity1 with advanced and unresectable @entity1721 ( @entity957 ) were enrolled into this study. Twenty-five of these 42 @entity1 were considered to have inoperable @entity5 due to distant organ @entity3 , distant lymph node @entity3 , severe organ dysfunction and rejection of surgery by the @entity1 . The remaining 17 @entity1 received neoadjuvant treatment followed by surgery. The clinical responses of the @entity5 were evaluated. RESULTS: Response and @entity137 could be assessed in 22 of the 25 @entity1 with unresectable esophageal @entity957 . Two of these 22 achieved a complete response (CR), 15 had a partial response (PR) and 5 showed no change (NC). The overall response rate (CR + PR) was 77%. The one- and 2-year survival rates were 30.7% and 10.2%, respectively, with a @entity1349 ( @entity1349 ) of 10.1 months. Of the 17 @entity1 who received neoadjuvant treatment, 14 underwent subsequent surgery. Preoperatively, 2 of these 17 @entity1 achieved a CR, 10 had a PR and 5 showed NC. The overall response rate for all 39 @entity1 was 74%. The pathological complete response (pCR) rate of the 14 @entity1 who underwent surgery was 28.6%. Their one- and 2-year survival rates were 48.2% and 12.1%, respectively, with an @entity1349 of 12.2 months. @entity137 was evaluated in the 39 @entity1 whose responses were assessed. @entity137 higher than grade 3 occurred in 8 out of 39 (20.5%) @entity1 , and 6 (15.4%), 3 (7.7%) and one (2.6%) had grade 3 @entity1431 , @entity882 and @entity417 , respectively. CONCLUSION: In conclusion, this study indicates that combination chemoradiotherapy with @entity1814 and @entity1487 is safe and efficacious for @entity1 with advanced @entity418 . We recommend further evaluation of this treatment regimen in such @entity1 .
